Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
GLUCOCORTICOID INHIBITORS FOR TREATMENT OF PROSTATE CANCER
Document Type and Number:
WIPO Patent Application WO/2015/089338
Kind Code:
A3
Abstract:
The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucocorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, GR inhibitors also have Androgen Receptor (AR) inhibitory activity or are administered in conjunction with AR inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes. The present invention also provides systems for using such agents, for example to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer.

Inventors:
ARORA VIVEK (US)
SAWYERS CHARLES L (US)
EVANS MICHAEL J (US)
VEACH DARREN R (US)
Application Number:
PCT/US2014/069854
Publication Date:
November 19, 2015
Filing Date:
December 11, 2014
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SLOAN KETTERING INST CANCER (US)
International Classes:
A01N45/00; A61K31/56; C07J71/00
Domestic Patent References:
WO2013126581A12013-08-29
Other References:
See also references of EP 3079475A4
Attorney, Agent or Firm:
LAUB, Friedrich, B. et al. (Hall & Stewart LLPTwo International Plac, Boston MA, US)
Download PDF: